
This study evaluates the long-term safety of zzso in patients with inflammatory zzso disease zzso treated with the drug over a zzso zzso 

The medical records of zzso patients with zzso treated with zzso and 666 control patients not treated with zzso were reviewed for adverse zzso The time of onset and outcome, severity and zzso medication were zzso 

Patients and controls were followed up for serious adverse events for a median time of 58 months zzso zzso and 144 months zzso zzso zzso 112 severe adverse events occurred in 93 patients zzso treated with zzso and 157 occurred in 126 zzso control patients zzso zzso zzso zzso zzso to zzso p zzso zzso There was no difference between the two groups in zzso zzso and infection zzso zzso was diagnosed in two patients receiving zzso who had negative skin tests at baseline whereas none of 16 patients with positive skin tests who received prophylaxis developed zzso zzso treatment with steroids was the only independent risk factor for infections in patients treated with zzso zzso zzso zzso zzso zzso to zzso p zzso zzso The most commonly observed systemic side effects were skin zzso including zzso zzso in 150 patients zzso 

zzso zzso treatment had a good overall safety profile in the patient cohort zzso 

